Compare Citius Pharmaceuticals Inc (CTXR) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Alphabet Inc Class A — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Alphabet Inc Class A trades at $351.44 (market cap $4.24T). The key difference: Alphabet Inc Class A is far larger — about 311306.9× Citius Pharmaceuticals Inc's market cap, and Alphabet Inc Class A pays a 0.25% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Alphabet Inc Class A for 85 Days on average.
| CTXR | GOOGL | |
|---|---|---|
Market Cap | $13.62M | $4.24T |
Volume | 132,438 | 23,392,850 |
Sector | Health | Media |
52-Week High | $1.82 | $402.62 |
52-Week Low | $0.48 | $236.59 |
Typical Hold Time | 17 Days | 85 Days |
Enterprise Value | $3.79M | $4.13T |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Alphabet (GOOGL) trades at $353.47, up 0.85% with strong bullish momentum. The stock shows robust fundamentals with revenue growth from $350.0B in 2024 to $402.8B in 2025 and net income surging to $132.2B. Technical indicators signal bullish momentum with the current price above key support levels. Recent earnings beats and strong analyst consensus support continued upside potential.
Outlook remains positive with 87% analyst buy ratings and $431.83 price target representing 22% upside. Key risks include antitrust scrutiny and AI competition, but Alphabet's diversified revenue streams and strong cash flow position the company for sustained growth. The combination of technical strength and fundamental excellence suggests favorable risk-reward for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
